LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company will present at the UBS Global Life Sciences Conference (September 26-29, 2005) in New York.
Dr. Francis Pinto, CEO, will present for Pharming at the UBS Conference on September 29, 2005 at 8:30 am. Biotechnology and pharmaceutical companies invited to the conference will present to over 3400 attendees, including institutional investors from the United States, Europe and Asia-Pacific.
For further information on the UBS Global Life Sciences Conference, please visit http://www.ibb.ubs.com/Conferences/co_highlights.shtml.
Background on Pharming Group N.V. Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company's products include potential treatments for genetic disorders, medical and specialty products for surgical indications, and intermediates for various applications. Pharming has two products in late stage development - recombinant human C1 inhibitor for hereditary angioedema (Phase III) and recombinant human lactoferrin for nutritional use. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.